Clinical Trial Detail

NCT ID NCT02656706
Title BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors howard safran
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult

No variant requirements are available.